ONO Pharmaceutical Co. Ltd. and Bristol-Myers Squibb K.K. have received supplemental regulatory approval in Japan for their combination therapy using Opdivo® (nivolumab) and Yervoy® (ipilimumab) for the treatment of unresectable hepatocellular carcinoma $(HCC)$. This approval expands the use of these drugs, based on the positive results from the CheckMate -9DW study, which demonstrated a significant improvement in overall survival compared to lenvatinib or sorafenib monotherapy. The collaboration between ONO and Bristol-Myers Squibb marks a significant advancement in the treatment options for patients with this form of liver cancer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ONO Pharmaceutical Co. Ltd. published the original content used to generate this news brief on June 24, 2025, and is solely responsible for the information contained therein.